BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34075570)

  • 21. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
    Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
    Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways.
    Cheng M; Wang Q; Chen L; Zhao D; Tang J; Xu J; He Z
    Hum Pathol; 2022 May; 123():59-73. PubMed ID: 35219686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
    Shang C; Tang W; Pan C; Hu X; Hong Y
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
    Johannessen TC; Prestegarden L; Grudic A; Hegi ME; Tysnes BB; Bjerkvig R
    Neuro Oncol; 2013 Mar; 15(3):269-78. PubMed ID: 23258843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypes.
    Docquier A; Harmand PO; Fritsch S; Chanrion M; Darbon JM; Cavaillès V
    Clin Cancer Res; 2010 Jun; 16(11):2959-70. PubMed ID: 20410059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
    Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
    Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma.
    Liu B; Zhou J; Wang C; Chi Y; Wei Q; Fu Z; Lian C; Huang Q; Liao C; Yang Z; Zeng H; Xu N; Guo H
    Cell Death Dis; 2020 May; 11(5):384. PubMed ID: 32439916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.
    Zhang Z; Wang Z; Huang K; Liu Y; Wei C; Zhou J; Zhang W; Wang Q; Liang H; Zhang A; Wang G; Zhen Y; Han L
    Cancer Lett; 2019 Feb; 443():91-107. PubMed ID: 30529153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LncRNA NEAT1 promotes malignant phenotypes and TMZ resistance in glioblastoma stem cells by regulating let-7g-5p/MAP3K1 axis.
    Bi CL; Liu JF; Zhang MY; Lan S; Yang ZY; Fang JS
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33057597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
    Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
    Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.
    Ge X; Pan MH; Wang L; Li W; Jiang C; He J; Abouzid K; Liu LZ; Shi Z; Jiang BH
    Cell Death Dis; 2018 Nov; 9(11):1128. PubMed ID: 30425242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
    Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
    Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1).
    Xu J; Song J; Xiao M; Wang C; Zhang Q; Yuan X; Tian S
    Bioengineered; 2021 Dec; 12(2):11768-11781. PubMed ID: 34895074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
    Liang H; Chen Z; Sun L
    Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
    Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
    Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The RIP140 gene is a transcriptional target of E2F1.
    Docquier A; Augereau P; Lapierre M; Harmand PO; Badia E; Annicotte JS; Fajas L; Cavaillès V
    PLoS One; 2012; 7(5):e35839. PubMed ID: 22629304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.